Clinical trials: Oral Anticoagulant
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Myocardial Infarction, Acute, Left Ventricular Thrombus
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
APERITIF is a prospective randomized open-label, blinded end-point (PROBE) trial, nested in the ongoing the "FRENCHIE" registry, a French multicenter prospective observational study granted by "ANR-RHU Grand Emprunt", in which…
- Trial name
- APERITIF (NCT05077683)
- Testing
- Rivaroxaban 2.5 MG [Xarelto], DAPT strategy
- Where
- France
- Volunteers
- 560 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antithrombotic Agents
Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department
Antithrombotics with antiplatelet agents, vitamin K antagonist (VKA), heparin and related substances, and new oral anticoagulants are prescribed for arterial diseases, especially in secondary prevention of embolic disease in…
- Trial name
- RATED Registry (NCT02706080)
- Testing
- emergency
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Clermont-Ferrand
Novel Oral Anticoagulants, NOACs
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Individual differences in drug efficacy and adverse reactions are common in the clinical application of drugs. Individual differences are caused by many factors, among which genetic factors account for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT05764356
- Testing
- Detection of genotype and RNA profile in platelet and white blood cell, Indicators test related to coagulation function, Indicators test related to platelet function
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Peking University First Hospital
Ischemic Stroke, Atrial Fibrillation
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders, Brain Diseases
- Trial name
- CARE-AF (NCT06954610)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant…
- Trial name
- ALTERNATIVE (NCT03292666)
- Testing
- Oral Anticoagulant
- Where
- 2 sites in United States
- Volunteers
- 39,603 people
- Sponsor
- University of California, San Francisco
Ischaemic Stroke
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice.
- Trial name
- ELAN (NCT03148457)
- Testing
- Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
- Where
- 98 sites in Austria, Belgium and 13 more
- Volunteers
- 2,013 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Long-term Oral Anticoagulant Therapy
Bemiparin Randomized Trial on Bridging Oral Anticoagulants in Invasive Procedures (BERTA Study)
Often it is necessary to temporarily discontinue OAT when surgical or other invasive procedures are required. However, there is no consensus on the optimal management in these situations, and heparin bridging therapy is the…
- Trial name
- BERTA (NCT00484822)
- Testing
- Bemiparina Sodica, Heparina Cálcica
- Where
- 31 sites in Spain
- Volunteers
- 206 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis
DOAC in Unusual Site Venous Thrombosis
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein…
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis
- Trial name
- DUST (NCT03778502)
- Testing
- Direct Oral Anticoagulants
- Where
- 24 sites in United States, Canada and 8 more
- Volunteers
- 358 people
- Sponsor
- University of Malta
Venous Thromboembolism, Embolism and Thrombosis
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
- Conditions
- Venous Thromboembolism, Embolism and Thrombosis, Hip Fractures
- Trial name
- NCT00119457
- Testing
- TTP889
- Where
- 21 sites in Czechia, Denmark and 2 more
- Volunteers
- 300 people
- Sponsor
- vTv Therapeutics
Thromboembolism
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER I (NCT00291330)
- Testing
- dabigatran etexilate 150 mg, warfarin (INR 2-3)
- Where
- 250 sites in United States, Argentina and 27 more
- Volunteers
- 2,564 people
- Sponsor
- Boehringer Ingelheim
Acute Intracranial Hemorrhage
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
- Trial name
- NCT03661528
- Testing
- andexanet alfa, Usual Care
- Where
- 142 sites in United States, Austria and 22 more
- Volunteers
- 530 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Subdural Hematoma, Atrial Fibrillation
Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma
Subdural hematoma (SDH) is a common disorder that typically results from head trauma and has increased in prevalence in recent decades.
- Trial name
- ATTAACH (NCT05472766)
- Testing
- Direct Acting Oral Anticoagulant starting at Day 30, Direct Acting Oral Anticoagulant starting at Day 90
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Sunnybrook Health Sciences Centre
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03596502
- Testing
- Direct oral anticoagulants (DOACs), Warfarin
- Where
- Canada
- Volunteers
- 402,764 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Venous Thromboembolism, Deep Venous Thrombosis
Aspirin for the Prevention of Recurrent Venous Thromboembolism
To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism, Atherosclerosis
- Trial name
- NCT00222677
- Testing
- aspirin
- Where
- 15 sites in Austria, Italy
- Volunteers
- 70 people
- Sponsor
- University Of Perugia
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Anticoagulants and Bleeding Disorders
Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy
Up to 5% of Atrial Fibrillation (AF) patients may have or develop contraindications to use oral anticoagulation (OAC). Randomized controlled trial (RCT) data suggest that Left Atrial Appendage Occlusion (LAAO) may provide a…
- Trial name
- COMPARE-LAAO (NCT04676880)
- Testing
- Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)
- Where
- 14 sites in Netherlands
- Volunteers
- 609 people
- Sponsor
- R&D Cardiologie
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Hemophilia A, Hemophilia B
Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia
Hemophilia is a rare X-linked bleeding disorder responsible for deficiency of coagulation factor VIII (FVIII) or IX (FIX). The main clinical manifestation is increased bleeding throughout the life which is directly correlated to…
- Conditions
- Hemophilia A, Hemophilia B, Anticoagulant-induced Bleeding
- Trial name
- KADOAH (NCT05804734)
- Testing
- Vitamin K Antagonist - Drug
- Where
- 6 sites in France
- Volunteers
- 54 people
- Sponsor
- Groupe Maladies hémorragiques de Bretagne
Behcet Disease, Behcet Disease and Vascular Involvement
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease.
- Conditions
- Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome
- Trial name
- BETTER (NCT06925698)
- Testing
- Rivaroxaban plus immunosupression
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Marmara University